Thrombosis and Hemostasis
Maker withdraws semuloparin applications
Credit: Andre E.X. Brown
In the wake of a negative review by an FDA advisory panel, the makers of semuloparin have decided to pull all applications to market the drug.
This information, as well as the withdrawal letter, will be published on the EMA website after the Committee for Medicinal Products for Human Use meeting, which is taking place July 16-19.
Notify me when a comment is posted for this article
In This Section